Inhibition of PI3K/mTOR Pathways In Glioblastoma and Implications for Combination Therapy with Erlotinib, Temozolomide, and Radiation

被引：0
|
作者：
Prasad, G. [1 ]
Sottero, T. [1 ]
Yang, X. [1 ]
Mueller, S. [1 ]
James, D. [1 ]
Berger, M. [1 ]
Aftab, D. T. [2 ]
Prados, M. D. [1 ]
Haas-Kogan, D. A. [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Exelixis Inc, San Francisco, CA USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2009年 / 75卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2009.07.172
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [1] INHIBITION OF PI3K/MTOR PATHWAYS IN GLIOBLASTOMA AND IMPLICATIONS FOR COMBINATION THERAPY WITH ERLOTINIB, TEMOZOLOMIDE, AND RADIATION
    Prasad, Gautam
    Sottero, Theo
    Yang, Xiaodong
    Mueller, Sabine
    James, C. David
    Polley, Mei-Yin C.
    Berger, Mitchel S.
    Aftab, Dana
    Prados, Michael
    Haas-Kogan, Daphne
    NEURO-ONCOLOGY, 2009, 11 (05) : 593 - 593
  • [2] Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
    Prasad, Gautam
    Sottero, Theo
    Yang, Xiaodong
    Mueller, Sabine
    James, C. David
    Weiss, William A.
    Polley, Mei-Yin
    Ozawa, Tomoko
    Berger, Mitchel S.
    Aftab, Dana T.
    Prados, Michael D.
    Haas-Kogan, Daphne A.
    NEURO-ONCOLOGY, 2011, 13 (04) : 384 - 392
  • [3] PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
    Babichev, Yael
    Kabaroff, Leah
    Datti, Alessandro
    Uehling, David
    Isaac, Methvin
    Al-awar, Rima
    Prakesch, Michael
    Sun, Ren X.
    Boutros, Paul C.
    Venier, Rosemarie
    Dickson, Brendan C.
    Gladdy, Rebecca A.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [4] PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
    Yael Babichev
    Leah Kabaroff
    Alessandro Datti
    David Uehling
    Methvin Isaac
    Rima Al-awar
    Michael Prakesch
    Ren X. Sun
    Paul C. Boutros
    Rosemarie Venier
    Brendan C. Dickson
    Rebecca A. Gladdy
    Journal of Translational Medicine, 14
  • [5] MAPkinase and PI3K/mTOR pathways inhibition in conjunctival melanoma
    Ei-Zaoui, Ikram El Zaoui
    Nicolas, Michael
    Gobert, Rosanna Pescini
    Rimoldi, Donata
    Leyraz, Serge
    Rivolta, Carlo
    Moulin, Alexandre
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [6] Radiogenomic characterization of response to chemo-radiation therapy in Glioblastoma is associated with PI3K/AKT/mTOR and apoptosis signaling pathways
    Beig, Niha
    Prasanna, Prateek
    Hill, Virginia
    Verma, Ruchika
    Varadan, Vinay
    Madabhushi, Anant
    Tiwari, Pallavi
    MEDICAL IMAGING 2019: COMPUTER-AIDED DIAGNOSIS, 2019, 10950
  • [7] Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches
    Singh, Gursimran
    Rohit, Pankaj
    Kumar, Pankaj
    Aran, Khadga Raj
    MEDICAL ONCOLOGY, 2025, 42 (04)
  • [8] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Li, Xiaoman
    Wu, Changjing
    Chen, Nianci
    Gu, Huadi
    Yen, Allen
    Cao, Liu
    Wang, Enhua
    Wang, Liang
    ONCOTARGET, 2016, 7 (22) : 33440 - 33450
  • [9] Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
    Barzegar Behrooz, Amir
    Talaie, Zahra
    Jusheghani, Fatemeh
    Los, Marek J.
    Klonisch, Thomas
    Ghavami, Saeid
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [10] Combination of PI3K/mTOR Inhibition Demonstrates Efficacy in Human Chordoma
    Schwab, Joseph
    Antonescu, Cristina
    Boland, Patrick
    Healey, John
    Rosenberg, Andrew
    Nielsen, Petur
    Iafrate, John
    Delaney, Thomas
    Yoon, Sam
    Choy, Edwin
    Harmon, David
    Raskin, Kevin
    Yang, Cao
    Mankin, Henry
    Springfield, Dempsey
    Hornicek, Francis
    Duan, Zhenfeng
    ANTICANCER RESEARCH, 2009, 29 (06) : 1867 - 1871
12345